Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Bridgewater Associates LP

Bridgewater Associates LP raised its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 69.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,035 shares of the specialty pharmaceutical company’s stock after buying an additional 79,036 shares during the period. Bridgewater Associates LP’s holdings in Jazz Pharmaceuticals were worth $23,649,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of JAZZ. Pacer Advisors Inc. raised its stake in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after acquiring an additional 115,102 shares in the last quarter. GW&K Investment Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company’s stock valued at $57,142,000 after purchasing an additional 97,589 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Jazz Pharmaceuticals by 501.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company’s stock valued at $13,800,000 after purchasing an additional 93,422 shares during the period. Raymond James Financial Inc. purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $11,373,000. Finally, Charles Schwab Investment Management Inc. increased its position in Jazz Pharmaceuticals by 15.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company’s stock worth $75,801,000 after buying an additional 83,807 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 1.1 %

Shares of NASDAQ JAZZ opened at $102.91 on Wednesday. The stock has a market capitalization of $6.25 billion, a price-to-earnings ratio of 14.49, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The firm has a 50-day moving average price of $128.93 and a 200 day moving average price of $122.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of Jazz Pharmaceuticals stock in a transaction on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the transaction, the chief accounting officer now directly owns 7,012 shares of the company’s stock, valued at approximately $966,323.72. This represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,736 shares of company stock valued at $4,023,305. Corporate insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the subject of several research analyst reports. Needham & Company LLC restated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, April 10th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Truist Financial upped their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.